Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

6.01
-0.3000-4.75%
Post-market: 6.030.0200+0.33%19:55 EDT
Volume:2.51M
Turnover:15.15M
Market Cap:510.73M
PE:3.21
High:6.25
Open:6.21
Low:5.92
Close:6.31
52wk High:18.97
52wk Low:5.92
Shares:84.98M
Float Shares:80.63M
Volume Ratio:0.85
T/O Rate:3.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.87
EPS(LYR):1.87
ROE:82.50%
ROA:0.48%
PB:2.01
PE(LYR):3.21

Loading ...

PagerDuty Announces Third Quarter Fiscal 2026 Financial Results

THOMSON REUTERS
·
Nov 26, 2025

PagerDuty Inc Outlook FY Adj Income per Share of $1.11 - $1.12

THOMSON REUTERS
·
Nov 26, 2025

PagerDuty options imply 10.2% move in share price post-earnings

TIPRANKS
·
Nov 26, 2025

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

GlobeNewswire
·
Nov 25, 2025

ProMIS Neurosciences Announces Reverse Stock Split

GlobeNewswire
·
Nov 24, 2025

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

GlobeNewswire
·
Nov 24, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 24, 2025

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

GlobeNewswire
·
Nov 22, 2025

PagerDuty (PD): Assessing Valuation After Recent Share Slide and Shifting Growth Sentiment

Simply Wall St.
·
Nov 21, 2025

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

GlobeNewswire
·
Nov 20, 2025

CMSC Initiates Coverage on 3SBIO (01530) with "Strong Buy" Rating, Citing PD-1/VEGF Bispecific Antibody as Catalyst for Revaluation

Stock News
·
Nov 20, 2025

Fosun Pharma's HLX10 (Serplulimab) Included in Breakthrough Therapy Program for Gastric Cancer Treatment

Stock News
·
Nov 20, 2025

Truist Lowers Price Target on PagerDuty to $20 From $23, Keeps Buy Rating

MT Newswires Live
·
Nov 19, 2025

Suzhou Zelgen Biopharmaceuticals (688266.SH) Receives Clinical Trial Approval for ZG006 Injection in Combination with PD-1/PD-L1 Inhibitors and Chemotherapy (Etoposide/Carboplatin)

Stock News
·
Nov 18, 2025

Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

GlobeNewswire
·
Nov 13, 2025

PagerDuty (PD) Gets a Buy from RBC Capital

TIPRANKS
·
Nov 13, 2025

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

GlobeNewswire
·
Nov 13, 2025

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 12, 2025

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

GlobeNewswire
·
Nov 12, 2025

Press Release: Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Dow Jones
·
Nov 12, 2025